Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...
The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate ...
NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...
Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...
A new draft NICE guideline had proposed new age thresholds to guide GP referral for ovarian cancer investigation, to improve ...
Age based thresholds for blood tests to detect ovarian cancer should be introduced, the National Institute for Health and ...
Women with the BRCA gene mutations have a 60 to 80 percent chance of developing /topics/Breast_Cancer" class="cnnInlineTopic">breast cancer-- at least five times higher than the general population -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback